🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "significant breakthrough" in the fight against superbug strains of the bacteria, according to researchers.

A Worldwide Challenge

Cases of gonorrhoea are increasing globally, with estimates suggesting over 82 million infections per year. Particularly high rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary development in the reality of growing infection rates, the spread of superbugs and the highly restricted treatment choices presently on offer.”

Public health authorities are particularly alarmed about the increase in treatment-resistant strains. The global health body has listed it as a "priority pathogen". Recent surveillance revealed that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Approval

Zoliflodacin, alternatively called a brand name, was approved by the US FDA in December for treating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Researchers believe that specific application of this new drug will help hinder the development of resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, also received approval in the same week. This drug, which is employed against UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to bring it to fruition.

“This approval represents a significant shift in the therapy of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Clinical Trial Results and Global Access

As per data published in a prominent scientific publication, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This establishes an similar efficacy with the existing first-line therapy, which involves a dual-drug approach. The trial involved over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Doctors directly involved have voiced hope. Access to a one-pill regimen like this is seen as a "revolutionary step" for public health efforts. This is deemed essential to lessen the impact of the infection for patients and to halt the transmission of highly drug-resistant gonorrhoea around the world.